• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senseonics touts Humana reimbursement nod for Eversense CGM

October 25, 2019 By Sean Whooley

eversense-logoSenseonics (NYSE:SENS) said yesterday that Humana is now providing coverage for its Eversense continuous glucose monitoring system and insertion procedure.

Humana is the fifth-largest health insurer in the U.S. with 17 million patients in 50 states, Washington, D.C. and Puerto Rico, according to a news release. Its coverage policy with Senseonics makes patients with Type 1 and Type 2 diabetes that require insulin eligible for Eversense. The policy was made effective on October 22.

Eversense is a long-term, implantable CGM sensor with a transmitter that sends discreet vibrations to alert users of low or high glucose. The device can be removed, recharged and re-adhered without discarding the sensor. The system was launched in August 2018 and has since won FDA approval to enable nurse practitioners and physicians assistants, not just trained physicians, to implant and remove the device.

“Eversense and the insertion procedure being included in the Humana CGM policy once again validates that an increasing number of payers are supporting the value our long-term CGM provides to patients with diabetes,” Senseonics president & CEO Tim Goodnow said in prepared remarks. “We are especially pleased that access has been included for not only for the Type 1 diabetes patients but also for the Type 2 patients that require insulin. We are confident that Eversense can conveniently assist all patients in managing their diabetes.”

Just last week, Senseonics won reimbursement for the Eversense system from Health Care Service Corporation – Blue Cross Blue Shield.

In August, Germantown, Md.-based Senseonics touted data from a two-year post-market registry in Europe that showed no serious adverse events and a low rate of related adverse events after multiple sensor insertion and removal cycles. The company said 5,417 sensors were inserted, for a total 1,260 patient-years of followup. Over two years of data collection, 0.96% of patients experienced sensor-site infection and 0.66% showed irritation from the adhesive patch.

Also in August, the company touted real-world data from a study of 205 U.S. patients using Eversense over a 90-day wear period. That study reported zero device or procedure-related adverse events from Eversense implementation.

Shares of SENS were up 6.9% at $1.09 per share in midday trading today.

Filed Under: Business/Financial News, Diabetes, Featured Tagged With: Humana, Reimbursement, Senseonics

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS